Entecavir and Tenofovir Treatment in Patients With Hepatitis B Virus-Related Cirrhosis: A Comparison of Results of Two-Year Treatment

Creative Commons License

Alkan E., AKIN M., Tuna Y.

KLIMIK JOURNAL, vol.33, no.3, pp.264-269, 2020 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.5152/kd.2020.54
  • Journal Name: KLIMIK JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
  • Page Numbers: pp.264-269
  • Keywords: Chronic hepatitis B, cirrhosis, entecavir, tenofovir, DISOPROXIL FUMARATE, MANAGEMENT, EFFICACY, SAFETY
  • Akdeniz University Affiliated: Yes


Objective: Hepatitis B virus (HBV) infection is a common cause of cirrhosis and hepatocellular carcinoma. Interferons and nucleos(t)ide analogs are being used for the treatment of chronic HBV infection. Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the strongest oral antiviral agents. In this study, we aimed to investigate efficacy and safety of ETV and TDF in treatment of naive cirrhotic patients infected with HBV.